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O
n May 15, 2005, the Public 
Library of Science and the 
Government Accountability 
Project, a public interest legal 
group that advises and supports 
whistleblowers (www.whistleblower.
org), co-sponsored a private meeting 
near the Capitol Building in 
Washington, D. C. In the room were 
four of the most high proﬁ  le medical 
whistleblowers of recent times. All four 
have gone public with information 
about practices in medicine and 
medical research that they believe are 
risking the public’s health or safety 
[1–5]. One of them was David Graham, 
Associate Director in the United States 
Food and Drug Administration’s 
(FDA’s) Ofﬁ  ce of Drug Safety, whose 
research on rofecoxib (Vioxx) pointed 
to the serious cardiovascular risks of 
the drug [1]. Graham was speaking 
in his own capacity and was not 
representing the FDA. An anonymous 
ﬁ  fth whistleblower—a research scientist 
at a major drug company—participated 
by phone.  
The whistleblowers took turns to 
share their stories, including their 
accounts of retaliations they said 
they had faced from their employers 
on raising their concerns, which 
led to lawsuits by at least two of the 
whistleblowers [2,3]. The picture that 
emerged from these accounts—a picture 
of American medicine’s inappropriate 
ties with the pharmaceutical industry—
was deeply troubling. 
As the investigative medical 
journalist Jeanne Lenzer reports 
in her Essay for PLoS Medicine [6], 
the whistleblowers spoke of public 
regulatory agencies that are putting 
the interests of drug companies 
ahead of the safety of patients, and 
of pharmaceutical companies that 
allow their marketing departments to 
knowingly downplay serious side effects 
when promoting their drugs. And 
they spoke of the woefully inadequate 
protection offered to those in the 
medical community who feel morally 
compelled to blow the whistle.
It was Lenzer who conceived the 
idea for the meeting. She believed that 
important lessons would emerge from 
having these medical whistleblowers, 
who come from very different 
professional backgrounds, together in 
one room to share their experiences. 
It took her many months of planning. 
In particular, she needed to gain the 
trust of the industry research scientist, 
so that the scientist could feel sure 
that anonymity would be preserved.  
But all of her planning nearly came 
to nothing. At the last moment the 
original journal sponsor pulled out on 
the advice of its lawyers. 
Lenzer’s phone call to PLoS, 
enquiring whether we might step in, 
came just ten days before the event was 
due to happen. We took our own legal 
advice and then agreed to sponsor the 
roundtable. PLoS was eager to support 
this event, and willing to accept any 
small legal risks, because we believe 
that the issues raised will be of huge 
interest to the medical community, 
to the press, to patients, and to the 
broader public. Further, the event 
ﬁ  ts well with our own public service 
mission of making all scientiﬁ  c and 
medical research results freely and 
publicly available, and with our belief 
that transparency in the conduct and 
publication of research is important 
for public trust. And the topic of the 
roundtable was in line with other 
articles we have published highlighting 
the many ways in which medicine has 
become tightly entangled with industry, 
to the great detriment of patients 
[7–9].
The risks to a journal in sponsoring 
such an event are, of course, much 
smaller than the risks that the 
whistleblowers at the roundtable faced 
in going public with their stories. 
Studies have shown that whistleblowers 
in both public service and private 
industry almost always experience 
retaliation from their employers, with 
those employed longer experiencing 
greater retaliation [10,11]. They 
risk loss of earnings, intimidation, 
harassment, victimization, and personal 
abuse, and they traditionally receive 
little help from statutory authorities 
[12,13]. 
The Washington whistleblowers’ 
stories illustrate these issues. 
Psychiatrist Stefan Kruszewski 
described how he was ﬁ  red from his 
job at the Pennsylvania Department of 
Public Welfare (DPW) after alerting 
his seniors to prescribing practices 
across the state that he considered to 
be alarming and dangerous [2]. “I was 
ﬁ  red in a demeaning manner,” said 
Kruszewski, who has sued DPW over 
his ﬁ  ring. “My two ofﬁ  ces were emptied 
and the contents of these ofﬁ  ces were 
put in the gutter.” David Graham—
who testiﬁ  ed at a US Senate Finance 
Committee hearing on rofexocib 
(Vioxx), the FDA, and Merck [1]—said 
that there was a conspiracy by senior 
management at the FDA “to intimidate 
me ahead of the Senate testimony.” 
Both of these individuals contend that 
pharmaceutical industry inﬂ  uence 
over their employers (a state and a 
federal regulatory agency, respectively) 
played a part in the difﬁ  culties these 
individuals faced in getting their 
concerns heard [1,2].
Lenzer’s report will, we hope, 
spark discussion and debate about 
how American medicine—clinicians, 
researchers, regulatory agencies, and 
medical journals—can disentangle 
itself from the inﬂ  uence of the 
pharmaceutical industry. In the past, 
medical journals and their editors have 
played an important part in exposing 
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the complex relationships between the 
pharmaceutical industry and medicine 
[14–16], including between industry 
and the medical journals themselves 
[9]. PLoS Medicine will continue to 
look critically at these relationships. 
A common theme at the roundtable 
was that, armed with information, the 
public too could have an important 
role in unpicking these ties. “The 
pharma–FDA complex has to be 
dismantled,” said Graham, “and the 
American people have to insist on that, 
otherwise we’re going to have disasters 
like Vioxx that happen in the future.” 
Patients, health professionals, and even 
the industry itself all surely stand to 
gain from disentanglement.  
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